<DOC>
	<DOCNO>NCT01178099</DOCNO>
	<brief_summary>The purpose study measure exposure prasugrel 's active metabolite pharmacodynamic effect prasugrel treatment people Sickle Cell Disease ( SCD ) .</brief_summary>
	<brief_title>An Assessment Prasugrel Healthy Adults Sickle Cell Adults</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Are 50 100 kilogram ( kg ) , inclusive , time screen . Have sign inform consent . If female , agree use reliable method birth control study woman childbearing potential due surgical sterilization ( hysterectomy bilateral oophorectomy tubal ligation ) menopause . Control Subjects Are healthy adult determine medical history , physical examination , screen procedure . Sickle cell disease ( SCD ) Subjects Subjects hydroxyurea must stable dose 30 day prior enrollment without sign hematologic toxicity screening . SCD Subjects Are adult SCD ( hemoglobin SS [ HbSS ] , Hb S beta0 thalassemia , Hb SC Hb S beta+ thalassemia genotype ) without diagnosis acute vasoocclusive crisis ( VOC ) require medical intervention emergency department , infusion center , inpatient ) within month prior screen . Have concomitant medical illness ( example , terminal malignancy ) , opinion investigator , associate reduce survival expected treatment period ( approximately 1 month ) . Exhibit severe hepatic dysfunction ( cirrhosis , portal hypertension , alanine aminotransferase [ ALT ] aspartate aminotransaminase [ AST ] â‰¥3 time upper limit normal [ ULN ] ) . Exhibit severe renal dysfunction define CockcroftGault creatinine clearance &lt; 30 milliliter per minute ( ml/min ) , require chronic dialysis . Creatine clearance = [ ( 140Age ) * Mass ( kg ) ] \ [ 72 * Serum creatinine ( milligram per deciliter [ mg/dL ] ) ] . Exhibit contraindication antiplatelet therapy . Have history intolerance allergy approve thienopyridines . Exhibit sign symptom infection . Have hematocrit &lt; 18 % . Exhibit history bleed diathesis , bleed require inhospital treatment , papillary necrosis . Have active internal bleeding . Have history spontaneous bleed require inhospital treatment . Have gross hematuria &gt; 300 red blood cell ( RBC ) /highpowered field ( HPF ) urinalysis time screen . History previous intraocular hemorrhage require treatment surgery laser , evidence active intraocular haemorrhage . Have prior history transient ischemic attack ( TIA ) , ischemic stroke , hemorrhagic stroke intracranial hemorrhage . Have know history intracranial neoplasm , arteriovenous malformation , aneurysm . Have clinical finding , judgment investigator , associate increase risk bleeding . Have international normalize ratio ( INR ) know &gt; 1.5 ( INR test require study entry ) . Have recent surgery ( within 30 day prior screen ) schedule undergo surgery within next 60 day . Have recent history clinically significant menorrhagia . Have use aspirin , warfarin , thienopyridine 10 day prior enrollment . Have use nonaspirin nonsteroidal antiinflammatory drug ( NSAID ) 3 day prior enrollment . Anticipate use aspirin , warfarin , NSAID , thienopyridine antiplatelet agent study period . Are woman know pregnant , give birth within past 90 day , breastfeed . Regular use drug abuse and/or unacceptable positive finding urinary drug screening ( positive urinary drug screen sleep inducer pain medication subject SCD consider acceptable finding ) . Are currently enrol , discontinue within last 30 day , clinical trial involve investigational drug device offlabel use drug device , concurrently enrol type medical research judge scientifically medically compatible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>